Evaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological Conditions
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, [18F]-FEPPA.
研究概览
简要总结
Ultimately a marker of microglial activation could be used for large-scale quantitative brain imaging trials in Alzheimer Disease (AD), Parkinson Disease (PD) or Multiple Sclerosis (MS), specifically to investigate the agent as an objective biomarker in treatments aimed at reducing inflammatory changes in these conditions. The significance of this work lies in applying state-of-art quantitative neuroimaging tools to develop a relevant biomarker in individuals with neurodegenerative diseases with the intention of using this efficiently in large clinical imaging trials.
详细描述
The adaptation of imaging agents like [18F]-FEPPA as a biomarker of microglial activation in neurodegenerative and neuroinflammatory diseases requires human validation studies. Expanding upon our previous work with B-amyloid ligands (123I-IMPY, 123I MNI-187) for AD and dopamine transporter ligands (123I B-CIT, Altropane) for PD, we desire to develop and characterize [18F]-FEPPA as a potential marker for microglial activation in association with neuronal damage that may be applicable to multiple neurodegenerative and inflammatory diseases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Alzheimer's disease patients will be recruited for this study. The following criteria will be met for inclusion of AD subjects in this study:
- •The participant is 50 years or older.
- •Written informed consent is obtained.
- •Participants have a clinical diagnosis of probable Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria.
- •Clinical Dementia Rating Scale score ≤
- •Modified Hachinski Ischemia Scale score of ≤
- •For females, non-child bearing potential or a negative urine or blood pregnancy test on day of [18F]-FEPPA injection.
排除标准
- •Alzheimer's subjects will be excluded from participation for the following reasons:
- •The subject has a history of significant cerebrovascular disease.
- •The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness
- •The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.
- •Pregnancy
- •Inclusion Criteria:
- •The following criteria will be met for inclusion of PD subjects in this study:
- •The participant is 30 years or older.
- •Written informed consent is obtained.
- •Participants have a clinical diagnosis of Parkinson disease (at least two of the three cardinal symptoms: resting tremor, rigidity, bradykinesia).
- •Hoehn and Yahr ≤
- •For females, non-child bearing potential or a negative urine or blood pregnancy test on day of [18F]-FEPPA injection.
- •Exclusion Criteria:
- •Parkinson's subjects will be excluded from participation for the following reasons:
- •The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness
- •The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.
- •Pregnancy
- •Inclusion Criteria:
- •Multiple Sclerosis Subject Selection. Subjects who have a clinical diagnosis of Multiple Sclerosis (MS) will be recruited for this study. The following criteria will be met for inclusion of MS subjects in this study:
- •The participant is 18 years or older.
- •Written informed consent is obtained.
- •Participants have a clinical diagnosis of Multiple Sclerosis (per the 2005 Revised McDonald Criteria; Polman, et al., 2005).
- •Kurtzke Expanded Disability Status Scale (EDSS) ≤ 7.
- •For females, non-child bearing potential or a negative urine or blood pregnancy test on day of [18F]-FEPPA injection.
- •Exclusion Criteria:
- •MS subjects will be excluded from participation for the following reasons:
- •The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness
- •The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.
- •Pregnancy
研究组 & 干预措施
assess [18F]-FEPPA PET imaging
干预措施: [18F]-FEPPA (Drug)
结局指标
主要结局
The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, [18F]-FEPPA.
时间窗: one year
次要结局
未报告次要终点
研究者
Danna Jennings, MD
Principal Investigator
Institute for Neurodegenerative Disorders